Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript
SRPT earnings call for the period ending June 30, 2024.…
124,650$
-0,57%
Echtzeit-Aktienkurs Sarepta Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Sarepta Therapeutics Inc. Aktie
Sarepta Therapeutics falls on revenue miss, weak outlook By Investing.com
Sarepta Therapeutics falls on revenue miss, weak outlook…
Is Pfizers Pain Sarepta Therapeutics Gain? Dont Bet on It.
One companys negative results can increase scrutiny of anothers work.…
Sarepta Therapeutics: Herabstufung nach der 30-prozentigen Rally - Aktienanalyse
New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von der Citigroup:
Die Analysten der Citigroup stufen die Aktie des Biopharma-Unternehmens Sarepta Therapeutics Inc.…
Sarepta Therapeutics: Kurszielanhebung
New York (www.aktiencheck.de) - Rating-Update:
Gavin Clark-Gartner, Analyst von Evercore ISI, stuft die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN:…
Sarepta Therapeutics: Kursziel verbessert
New York (www.aktiencheck.de) - Rating-Update:
Die Analysten von Morgan Stanley stufen die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN: A1J1BH,…
Sarepta Therapeutics: Annahmen aktualisiert - Aktienanalyse
Boston, MA (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Leerink Partners:
Die Analysten von Leerink Partners erhöhen in einer aktuellen Aktienanalyse ihr Kursziel…
Sarepta Therapeutics: Kursziel gesteigert
New York (www.aktiencheck.de) - Rating-Update:
Die Analysten von Goldman Sachs bewerten die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN: A1J1BH,…
Sarepta Therapeutics: Monopol in Verbindung mit Bedarf bei DMD biete kommerzielle Chance - Aktienanalyse
Toronto (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von BMO Capital Markets:
Die Analysten von BMO Capital Markets erhöhen in einer aktuellen Aktienanalyse ihr…
Sarepta Therapeutics: Kursziel angehoben
New York (www.aktiencheck.de) - Rating-Update:
Die Analysten von Needham & Co stufen die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN:…
Sarepta Therapeutics: Kurszielerhöhung
Toronto (www.aktiencheck.de) - Rating-Update:
Die Analysten vom Investmenthaus RBC Capital Markets stufen die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN:…
Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?
Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…
Sarepta Therapeutics: Kursziel hochgesetzt
Charlotte (www.aktiencheck.de) - Rating-Update:
Tazeen Ahmad, Analyst von BofA Securities, stuft die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN: A1J1BH,…
Sarepta Therapeutics: Pushing The Edge And Creating The Horizon
…
Sarepta Therapeutics: Why Todays Rally On DMD Drug Label Expansion Wont Last
…
Stocks making the biggest moves midday: Sarepta Therapeutics, Hertz Global, Asana and more
These are the stocks posting the largest moves in midday trading.…
Sarepta Therapeutics shares surge as muscular dystrophy therapy approved for expanded use
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares soared almost 35% after the US Food and Drug Administration (FDA) approved the expanded use…
Sarepta Therapeutics shares surge on expanded approval of muscular dystrophy therapy
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares soared almost 35% after the US Food and Drug Administration (FDA) approved the expanded use…
Sarepta Therapeutics legt nach FDA-Zulassung stark zu - Aktiennews
Frankfurt (www.aktiencheck.de) - Sarepta Therapeutics legt nach FDA-Zulassung stark zu - Aktiennews
Sarepta Therapeutics (ISIN: US8036071004, WKN: A1J1BH, Ticker-Symbol: AB3A, NASDAQ-Symbol:…
Stocks making the biggest moves premarket: Gilead Sciences, Sarepta Therapeutics, Nike and more
These are the stocks posting the largest moves in premarket trading.…
Roche-Partner Sarepta Therapeutics-Aktie zündet Turbo nach FDA-Zulassung für Millionen-Dollar-Behandlung
• Sarepta Therapeutics erhält erweiterte FDA-Zulassung • Zusammenarbeit mit Roche bei Medikament gegen Muskelschwund • Sarepta Therapeutics-Aktie mit Kurssprung …
Market Rally Tries To Steady As AI Stocks Extend Losses
The Nasdaq and S&P 500 fell from record highs Thursday. Sarepta Therapeutics surged Friday on FDA approval.…
Top Stock Movers Now: FactSet, Sarepta Therapeutics, Spirit AeroSystems, and More
The Dow, S&P 500, and Nasdaq were little changed at midday Friday, June 21, 2024 as reports showed existing home…
Sarepta Therapeutics: Kräftiger Kurssprung nach Zulassungsneuigkeiten - Aktienanalyse
Kulmbach (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse vom Online-Anlegermagazin "Der Aktionär":
Michel Doepke von "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die des…
Sarepta Therapeutics surges 36% after-hours following expanded FDA approval By Investing.com
Sarepta Therapeutics surges 36% after-hours following expanded FDA approval…
Sarepta Therapeutics: Navigating Elevidys Upside Potential
…
Sarepta Therapeutics gains as Pfizer failure removes overhang By Investing.com
Sarepta Therapeutics gains as Pfizer failure removes overhang…
Sarepta Therapeutics: Pfizer-Versagen beseitigt Überhang - Aktienanalyse
London (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Barclays:
Gena Wang, Analystin von Barclays, nimmt in einer aktuellen Aktienanalyse die Aktie von Sarepta…
Sarepta Therapeutics to replace Shockwave Medical in the S&P MidCap 400
…
Mizuho raises Sarepta Therapeutics stock target on FDA hopes By Investing.com
Mizuho raises Sarepta Therapeutics stock target on FDA hopes…
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
SRPT earnings call for the period ending March 31, 2024.…
Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript
…
Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
…
Sarepta Therapeutics: Another Hold Call Ahead Of Some Key Catalysts
…
5 Small Biotech ETFs to Watch (Updated 2024)
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
The upcoming regulatory decision on its latest drug could be big.…
UBS raises Sarepta Therapeutics shares target on label outlook By Investing.com
UBS raises Sarepta Therapeutics shares target on label outlook…
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
SRPT earnings call for the period ending December 31, 2023.…
Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript
…
Is It Too Late to Buy Sarepta Therapeutics Stock?
The companys hyperfocus on its core area could continue to be highly lucrative.…
The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron
Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron are included in this Analyst Blog.…
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
Its always tough to be compared to a giant.…
Sarepta Therapeutics: Leading The Way In DMD Treatment With Gene Therapy Innovations
…
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
One pundit feels there is solid potential in one of the companys more recently approved drugs.…
Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
…
Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains?
Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions…
Sarepta Therapeutics shares rally, Mizuho says confidence in label expansion remains unwavering By Investing.com
Sarepta Therapeutics shares rally, Mizuho says confidence in label expansion remains unwavering…
Sarepta Therapeutics provides Q4 and FY forecast
…
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
Both develop medicines for rare diseases, and each aims to conquer a niche market.…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…